![]() |
Volumn 30, Issue 1, 2002, Pages 147-156
|
The Trp53 hemizygous mouse in pharmaceutical development: Points to consider for pathologists
|
Author keywords
Alternative model; Bioassay; Cancer; Carcinogenicity; Genetically modified; Knockout; p53; Short term assay; Tumor
|
Indexed keywords
4 CRESIDENE;
BENZENE;
CARCINOGEN;
DNA;
GENE PRODUCT;
PARA CRESOL;
PROTEIN P53;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
CANCER INCIDENCE;
CARCINOGEN TESTING;
CELL PROLIFERATION;
CONTROLLED STUDY;
DECISION MAKING;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC PROCEDURE;
DISEASE MODEL;
DOSE RESPONSE;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
FEMALE;
HEMIZYGOSITY;
HISTOPATHOLOGY;
HYPERPLASIA;
MALE;
MAXIMUM ALLOWABLE CONCENTRATION;
MAXIMUM TOLERATED DOSE;
MOUSE;
NEOPLASM;
NONHUMAN;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
PROCESS DESIGN;
SARCOMA;
STATISTICAL ANALYSIS;
SUBCUTANEOUS TISSUE;
SURVIVAL;
THYMOMA;
TRANSGENIC MOUSE;
TRP53 GENE;
TUMOR SUPPRESSOR GENE;
ANIMALS;
BIOLOGICAL ASSAY;
CARCINOGENICITY TESTS;
DRUG INDUSTRY;
GENES, P53;
GENES, TUMOR SUPPRESSOR;
MICE;
MICE, TRANSGENIC;
NEOPLASMS;
PATHOLOGY;
PHARMACOLOGY;
ANIMALIA;
MUS MUSCULUS;
RODENTIA;
|
EID: 0036185657
PISSN: 01926233
EISSN: None
Source Type: Journal
DOI: 10.1080/01926230252824860 Document Type: Article |
Times cited : (11)
|
References (36)
|